Vanguard Group Inc Viracta Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 289,174 shares of VIRX stock, worth $5,783. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,174

Previous 954,485 69.7%

Holding current value

$5,783

Previous $219,000 79.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$0.14 - $0.26 $93,143 - $172,980	-665,311 Reduced 69.7%	289,174 $46,000
Q3 2024 Nov 13, 2024	SELL	$0.21 - $0.56 $43,426 - $115,805	-206,795 Reduced 17.81%	954,485 $219,000
Q4 2023 Feb 14, 2024	BUY	$0.44 - $1.04 $5,881 - $13,902	13,368 Added 1.16%	1,161,280 $661,000
Q4 2022 Feb 10, 2023	BUY	$1.26 - $4.38 $42,265 - $146,922	33,544 Added 3.01%	1,147,912 $1.68 Million
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $687,598 - $1.18 Million	207,108 Added 22.83%	1,114,368 $4.76 Million
Q2 2022 Aug 12, 2022	BUY	$1.87 - $5.0 $146,576 - $391,915	78,383 Added 9.46%	907,260 $3.52 Million
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $1.39 Million - $2.98 Million	-625,449 Reduced 43.01%	828,877 $3.95 Million
Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $32,726 - $76,814	9,711 Added 0.67%	1,454,326 $5.31 Million
Q3 2021 Nov 12, 2021	BUY	$7.84 - $12.53 $83,833 - $133,983	10,693 Added 0.75%	1,444,615 $11.6 Million
Q2 2021 Aug 13, 2021	BUY	$7.55 - $12.95 $10.8 Million - $18.6 Million	1,433,922 New	1,433,922 $16.3 Million

Others Institutions Holding VIRX

# of Institutions

Shares Held

3.66M

Call Options Held

1.8K

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $751K
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Viracta Therapeutics, Inc. Transaction History